lymph node dissection: The extent of lymph node dissection varies between groups
Study summary
To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants are aged 18-75;
* Colonoscopy biopsy confirms colorectal adenocarcinoma;
* Colonoscopy shows that the lower edge of the tumor is located more than 10 cm from the margin or the tumor is located in the upper rectum and sigmoid colon by imaging diagnosis;
* The tumor is staged cT1-4aNxM0 by preoperative imaging;
* Participants have no local complications before surgery.
Exclusion Criteria:
* Previous history of malignant colorectal tumor;
* Multiple primary colorectal tumors;
* Preoperative imaging reveals suspicious positive lymph nodes in the submesenteric artery root region (area 253);
* Patients undergoing neoadjuvant therapy before surgery;
* With contraindications to laparoscopic surgery;
* Histoty of multiple abdominal and pelvic surgery or extensive abdominal adhesions;
* Other malignancies were diagnosed within the past 5 years;
* History of severe mental illness;
* Pregnant or lactating women;
* With uncontrolled infection before surgery.
Primary outcome measure(s)
Disease-free survival — The endpoint of the disease-free survival assessment is the last follow-up or disease recurrence. Follow-up time is up to 36 months. Disease-free survival is defined as the time from the surgery to disease recurrence or last follow-up, which was measured in months.
Overall survival — The endpoint of the overall survival assessment is the last follow-up or patient death. Follow-up time is up to 36 months. Overall survival is defined as the time from the surgery to death or last follow-up, regardless of disease recurrence, which was measured in months.
Trial sites (19)
Facility
City
Region
Status
The First Affiliated Hospital of University of Science and Technology of China
Hefei
Anhui
Cancer Hospital Chinese Academy of Medical Sciences
Beijing
Beijing Municipality
The First Affiliated Hospital of Chengdu Medical College
Chengdu
Chengdu
Fujian Province Tumor Hospital
Fuzhou
Fujian
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou
Guangdong
Guangdong Provincial People's Hospital
Guangzhou
Guangdong
Nanfang Hospital of Southern Medical University
Guangzhou
Guangdong
Hebei Medical University Fourth Hospital
Shijiazhuang
Hebei
The Second Affiliated Hospital of Harbin Medical University
Haerbin
Heilongjiang
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing
Jiangsu
Jiangxi Provincial Cancer Hospital
Nanchang
Jiangxi
The First Hospital of Jilin University
Changchun
Jilin
Shengjing Hospital
Shenyang
Liaoning
Qinghai University Affiliated Hospital
Xining
Qinghai
Binzhou Medical University
Binzhou
Shandong
Fudan University Shanghai Cancer Center
Shanghai
Shanghai Municipality
Shanxi Cancer Hospital
Taiyuan
Shanxi
The Second People's Hospital of Yibin
Yibin
Sichuan
The second People's Hospital of Yunnan Province
Kunming
Yunnan
More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.